Myriad Genetics, Inc. (MYGN) Earnings
Myriad Genetics, Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $-0.03. MYGN has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +170.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.06 | $-0.09 | -50.0% | $200M | -1.0% |
| Feb 23, 2026 | $-0.02 | $0.04 | +300.0% | $210M | +0.7% |
| Nov 7, 2024 | $0.02 | $0.06 | +215.8% | $213M | -0.1% |
| Feb 27, 2024 | $0.01 | $0.04 | +214.2% | $197M | +0.9% |
| Aug 3, 2023 | $-0.10 | $-0.08 | +20.0% | $184M | -1.9% |
| May 3, 2023 | $-0.19 | $-0.21 | -10.5% | $181M | +5.6% |
| Feb 28, 2023 | $-0.16 | $-0.12 | +25.0% | $178M | +4.9% |
| Nov 1, 2022 | $-0.06 | $-0.19 | -216.7% | $156M | -8.0% |
| Aug 4, 2022 | $0.01 | $0.04 | +300.0% | $179M | +4.9% |
| May 5, 2022 | $-0.05 | $-0.03 | +40.0% | $165M | +5.3% |
| Feb 24, 2022 | $-0.02 | $-0.02 | -14.3% | $161M | -1.3% |
| Nov 2, 2021 | $0.01 | $-0.02 | -300.0% | $167M | +0.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Prioritization of cancer care continuum: Invested in commercial capabilities and R&D for cancer care continuum, with significant investments this year. • Strengthened organization: Added leaders with oncology, genomics, and advanced diagnostics expertise. • Strengthened execution and agility: Implemented new decision-making processes, simplified structure. • Q1 results: Revenue within guidance, 385,000 test results, strong hereditary cancer testing volume growth, solid mental health growth, prenatal volume showing stabilization. • Cancer care continuum strategy: March launch of Precise MRD breast cancer for select customers, on track for Prolaris prostate cancer test launch in June, updates on Precise MRD commercialization plan. • CCO Brian Donnelly's updates: Cancer care continuum business growth, Prolaris investment, Precise MRD progress, prenatal business stabilization, first gene progress, commercial capabilities investment. • CFO Ben Wheeler's updates: Product category messaging simplification, key drivers of Q1 performance, consolidated financial results, profitability and liquidity, reaffirmed full-year guidance.
Guidance
• Reaffirmed 2026 financial guidance: Revenue $860 - $880 million, adjusted gross margin 68% - 69%, adjusted EBITDA $37 - $49 million. • Expect sequential revenue growth from Q2, with second half stronger than first half, driven by business trends, prenatal portfolio improvement, commercial team expansion, and revenue cycle initiatives.
Segment performance
Revenue in Q1 was just over $200 million. Cancer care continuum product category (including affected and unaffected hereditary cancer testing and other genomic testing) generated $120.2 million revenue, up 4% YOY; hereditary cancer testing volume grew 14%, with unaffected population growth stronger. Prolaris in prostate cancer had mid-single-digit growth in volume and revenue. Mental health: GeneSight had 24% YOY revenue growth and 7% test volume growth. Prenatal volume declined YOY but showed quarter-over-quarter growth, with first gene in early access clinical testing and strong enrollment momentum.
Analyst Q&A
Q: Kyle Boucher asked about revenue ramp through back half of year and balancing launch investment with EBITDA profitability.
A: Sam and Ben responded about confidence in guidance from hereditary cancer growth, GeneSight performance, prenatal improvement, and sales team contributions, and about balancing investments through timing and people focus.
Q: Kyle Peterson asked about hereditary strengths delineation and precise MRD pull forward.
A: Sam and Brian responded about unaffected market growth, MIRAS panel, EMR integration, and rationale for pulling forward CRC and renal due to customer interest.
Q: Puneet Sudha asked about commercial side updates.
A: Stephanie, Brian, and Sam responded about sales team expansion, focused sales teams, productivity, and portfolio focus on cancer care continuum.
Q: David Westenberg asked about AI-enabled prostate cancer test positioning and gene site revenue.
A: Brian and Ben responded about test positioning, sales training, and gene site ASP improvement and sustainability.
Q: Brandon Quillard asked about prenatal business reacceleration.
A: Sam, Brian, and Ben responded about dedicated sales team, first gene differentiation, and commercial execution.
Q: Subbu Nambi asked about first gene reimbursement and gross margin.
A: Ben and Sam responded about reimbursement using existing codes and gross margin accretive nature.
Q: Mason Carrico asked about sales team split and prenatal reacceleration.
A: Sam and Brian responded about sales team focus on cancer care continuum and first gene's role in prenatal reacceleration